This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.
KRAS P.G12C
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.
A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
-
D3 Bio Investigative Site, Orange, California, United States, 92868
D3 Bio Investigative Site, Denver, Colorado, United States, 80218-1238
D3 Bio Investigative Site, Sarasota, Florida, United States, 34232-6410
D3 Bio Investigative Site, Detroit, Michigan, United States, 48202-2608
D3 Bio Investigative Site, Nashville, Tennessee, United States, 37203
D3 Bio Investigative Site, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
D3 Bio (Wuxi) Co., Ltd,
Cheng Chen, MD, STUDY_DIRECTOR, D3 Bio (Wuxi) Co., Ltd
2026-09